Overview

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

Status:
Unknown status
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
Chronic hepatitis C virus infection affects an estimated one hundred and seventy million people around the world with and approximate prevalence 0.2-2 % in the United State of America and European countries.
Phase:
Phase 3
Details
Lead Sponsor:
Assiut University
Treatments:
Antiviral Agents
Sofosbuvir